Tenax Therapeutics (TENX) Total Non-Current Liabilities (2012 - 2022)
Tenax Therapeutics (TENX) posted quarterly Total Non-Current Liabilities of $64196.0 for Q4 2022, down 65.03% year-over-year from $183589.0 in Q4 2021, and down 32.67% on a QoQ basis from $95347.0 in Q3 2022.
Tenax Therapeutics (TENX) Total Non-Current Liabilities (2012 - 2022) Analysis & Trends
Tenax Therapeutics has reported Total Non-Current Liabilities for 10 years, with the latest figure at $64196.0 in Q4 2022.
- Total Non-Current Liabilities for Q4 2022 came in at $64196.0, down 65.03% year-over-year; the trailing twelve-month figure through Dec 2022 was $64196.0 (down 65.03% YoY), and the FY2022 annual result was $64196.0, down 65.03% from the prior year.
- Total Non-Current Liabilities slipped to $64196.0 in Q4 2022, from $95347.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $1.6 million in Q4 2018 and troughed at $31080.0 in Q1 2021.
- A 5-year average of $296837.4 and a median of $169306.5 in 2021 frame the typical range for Total Non-Current Liabilities.
- The widest annual swing landed in 2019, when Total Non-Current Liabilities slumped 96.11%; it then jumped 398.79% in 2022.
- A 5-year view of Total Non-Current Liabilities shows it stood at $1.6 million in 2018, then slumped by 96.11% to $60379.0 in 2019, then jumped by 105.64% to $124166.0 in 2020, then jumped by 47.86% to $183589.0 in 2021, then slumped by 65.03% to $64196.0 in 2022.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $64196.0 in Q4 2022, $95347.0 in Q3 2022, and $125883.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Tenax Therapeutics | 78.47 Mn | 78.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 64,196.00 |
| Sep 30, 2022 | 95,347.00 |
| Jun 30, 2022 | 125,883.00 |
| Mar 31, 2022 | 155,024.00 |
| Dec 31, 2021 | 183,589.00 |
| Sep 30, 2021 | 211,590.00 |
| Jun 30, 2021 | 239,039.00 |
| Mar 31, 2021 | 31,080.00 |
| Dec 31, 2020 | 124,166.00 |
| Sep 30, 2020 | 213,757.00 |
| Jun 30, 2020 | 137,051.00 |
| Dec 31, 2019 | 60,379.00 |
| Dec 31, 2018 | 1.55 Mn |
| Sep 30, 2018 | 496,782.00 |
| Jun 30, 2018 | 768,240.00 |
| Mar 31, 2018 | 290,339.00 |
| Dec 31, 2017 | 975,167.00 |
| Sep 30, 2017 | 802,474.00 |
| Jun 30, 2017 | 2.11 Mn |
| Mar 31, 2017 | 4.99 Mn |